TY - JOUR
T1 - Interleukin-6 stimulates lipolysis and fat oxidation in humans
AU - van Hall, Gerrit
AU - Steensberg, Adam
AU - Sacchetti, Massimo
AU - Fischer, Christian
AU - Keller, Charlotte
AU - Schjerling, Peter
AU - Hiscock, Natalie
AU - Møller, Kirsten
AU - Saltin, Bengt
AU - Febbraio, Mark A
AU - Pedersen, Bente K
PY - 2003/7
Y1 - 2003/7
N2 - Although IL-6 is a key modulator of immune function, it also plays a role in regulating substrate metabolism. To determine whether IL-6 affects lipid metabolism, 18 healthy men were infused for 3 h with saline (Con; n = 6) or a high dose (High-rhIL6; n = 6) or a low dose (Low-rhIL6; n = 6) of recombinant human IL-6 (rhIL-6). The IL-6 concentration during Con, Low-rhIL6, and High-rhIL6 was at a steady state after 30 min of infusion at approximately 4, 140, and 320 pg/ml, respectively. Either dose of rhIL-6 was associated with a similar increase in fatty acid (FA) concentration and endogenous FA rate of appearance (R(a)) from 90 min after the start of the infusion. The FA concentration and FA R(a) continued to increase until the cessation of rhIL-6 infusion, reaching levels approximately 50% greater than Con values. The elevated levels reached at the end of rhIL-6 infusion persisted at least 3 h postinfusion. Triacylglycerol concentrations were unchanged during rhIL-6 infusion, whereas whole body fat oxidation increased after the second hour of rhIL-6 infusion. Of note, during Low-rhIL6, the induced elevation in FA concentration and FA R(a) occurred in the absence of any change in adrenaline, insulin, or glucagon, and no adverse side effects were observed. In conclusion, the data identify IL-6 as a potent modulator of fat metabolism in humans, increasing fat oxidation and FA reesterification without causing hypertriacylglyceridemia.
AB - Although IL-6 is a key modulator of immune function, it also plays a role in regulating substrate metabolism. To determine whether IL-6 affects lipid metabolism, 18 healthy men were infused for 3 h with saline (Con; n = 6) or a high dose (High-rhIL6; n = 6) or a low dose (Low-rhIL6; n = 6) of recombinant human IL-6 (rhIL-6). The IL-6 concentration during Con, Low-rhIL6, and High-rhIL6 was at a steady state after 30 min of infusion at approximately 4, 140, and 320 pg/ml, respectively. Either dose of rhIL-6 was associated with a similar increase in fatty acid (FA) concentration and endogenous FA rate of appearance (R(a)) from 90 min after the start of the infusion. The FA concentration and FA R(a) continued to increase until the cessation of rhIL-6 infusion, reaching levels approximately 50% greater than Con values. The elevated levels reached at the end of rhIL-6 infusion persisted at least 3 h postinfusion. Triacylglycerol concentrations were unchanged during rhIL-6 infusion, whereas whole body fat oxidation increased after the second hour of rhIL-6 infusion. Of note, during Low-rhIL6, the induced elevation in FA concentration and FA R(a) occurred in the absence of any change in adrenaline, insulin, or glucagon, and no adverse side effects were observed. In conclusion, the data identify IL-6 as a potent modulator of fat metabolism in humans, increasing fat oxidation and FA reesterification without causing hypertriacylglyceridemia.
KW - Adult
KW - Energy Metabolism/drug effects
KW - Epinephrine/blood
KW - Fatty Acids/metabolism
KW - Glucagon/blood
KW - Glycerol/metabolism
KW - Humans
KW - Hydrocortisone/blood
KW - Insulin/blood
KW - Interleukin-6/administration & dosage
KW - Lipolysis/drug effects
KW - Male
KW - Norepinephrine/blood
KW - Oxidation-Reduction
KW - Oxygen Consumption/drug effects
KW - Recombinant Proteins/administration & dosage
KW - Triglycerides/metabolism
U2 - 10.1210/jc.2002-021687
DO - 10.1210/jc.2002-021687
M3 - Journal article
C2 - 12843134
SN - 0021-972X
VL - 88
SP - 3005
EP - 3010
JO - The Journal of clinical endocrinology and metabolism
JF - The Journal of clinical endocrinology and metabolism
IS - 7
ER -